The Paradigm (ASX:PAR) share price is up 11% on Tuesday

It’s been a great week for the company’s shareholders…

| More on:
Man puts thumb up next to stock market graph

Image source: Getty Images

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has strongly rebounded after hitting a 52-week low of $1.76 last week. This comes as the biopharmaceutical company released two positive announcements in the past few days.

At the time of writing, Paradigm shares are up 11.88% to $2.26 apiece. It’s worth noting that this means its share price is also up almost 25% since last Tuesday.

What’s driving Paradigm shares higher?

Investors appear to have found the bottom of the Paradigm share price following its recent surge.

During market trade on Friday, the company released a positive update.

Paradigm stated that it received an Australian ethics approval for its pivotal phase 3 clinical trial, PARA_OA_002. The study is aiming to assess treatment of pentosan polysulfate sodium (PPS) against placebo on participants with Knee Osteoarthritis Pain.

Patient recruitment and screening are yet to commence until later this year. The company has identified several sites to conduct the Australian arm of its clinical study.

The other announcement came yesterday, with Paradigm revealing that there has been a response from the United States Food and Drug Administration (FDA). This is in relation to its Investigational New Drug (IND) application to begin the United States arm of the study.

According to the notice, the FDA posed just one question about the adrenal gland function. A preclinical finding in the adrenal gland had been indicated in rats only but not in dogs. Paradigm noted that it has not seen a malfunction of the adrenal gland by itself or bene pharmaChem.

As such, the FDA has requested modifications to the company’s adrenal screening and mitigation plan.

Paradigm plans to amend its clinical trial protocol, and respond to the FDA within the next week.

The company’s CEO, Paul Rennie said that he’s confident that the FDA and Paradigm have attained a pathway to commence a phase 3 clinical trial in the United States.

About the Paradigm share price

It has been a whirlwind 12 months for Paradigm shares, reaching highs of $3 late last year, before treading lower. Since September 2020, its shares have fallen around 6%, with year-to-date down 11%.

Based on today’s price, Paradigm presides a market capitalisation of roughly $513.5 million and has approximately 227 million shares outstanding.

Should you invest $1,000 in Paradigm right now?

Before you consider Paradigm, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Paradigm wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares